A dual label oligonucleotide ligation assay for detection of the CYP2C19*1, CYP2C19*2, and CYP2C19*3 alleles involving time-resolved fluorometry

被引:11
|
作者
Bathum, L
Hansen, TS
Horder, M
Brosen, K
机构
[1] Odense Univ Hosp, Dept Clin Biochem, DK-5000 Odense C, Denmark
[2] Odense Univ, Dept Clin Pharmacol, DK-5230 Odense, Denmark
关键词
CYP2C19; genotyping; genetic polymorphism;
D O I
10.1097/00007691-199802000-00001
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
CYP2C19 (S-mephenytoin hydroxylase) is a polymorphically expressed enzyme. Currently, two defective alleles are known-CYP2C19*2 and CYP2C19*3. The authors have developed an oligonucleotide ligation assay to detect these two alleles. This assay combines the hybridization of one common, biotinylated capture probe and two allele-specific probes to the target DNA, with the ability of a DNA ligase to distinguish mismatched nucleotides. The probes are only ligated if they are base paired correctly to the target strand. The biotin is bound to streptavidin, and all DNA not covalently bound to the biotin-labeled capture probe, is removed in a washing procedure. The allele-specific probes are labeled with either europium or samarium, and their emission can be measured simultaneously. The ratio between the emission separates the genotypes. This method was applied on DNA from 19 whites and 21 Vietnamese living in Denmark. All genotypes determined by the assay were consistent with the results from restriction enzyme cleavage. There were 12 poor metabolizers; 10 homozygous CYP2C19*2/CYP2C19*2, one heterozygous CYP2C19*2/CYP2C19*3, and one heterozygous CYP2C19*1/CYP2C19*2. The authors conclude that this assay is well-suited for a high throughput of samples in a routine laboratory. The finding of an apparently heterozygous CYP2C19*1/CYP2C19*2 poor metabolizer, confirms that there are still unknown mutations in CYP2C19.
引用
收藏
页码:1 / 6
页数:6
相关论文
共 50 条
  • [41] CYP2C19*2 polymorphism and clopidogrel resistance
    Joob, Beuy
    Wiwanitkit, Viroj
    ARCHIVOS DE CARDIOLOGIA DE MEXICO, 2020, 90 (04): : 505 - 505
  • [42] Prevalence of CYP2C19*2 and CYP2C19*3 Allelic Variants and Clopidogrel Use in Patients with Cardiovascular Disease in Trinidad & Tobago
    Jones, Daniele
    Persad-Ramdeensingh, Shana
    Abrahim, Sheherazade Crystal
    Seecheran, Naveen
    Haraksingh, Rajini Rani
    CARDIOLOGY AND THERAPY, 2024, 13 (01) : 191 - 203
  • [43] Association between blood carisoprodol:: meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers:: decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects?
    Bramness, JG
    Skurtveit, S
    Fauske, L
    Grung, M
    Molven, A
    Morland, J
    Steen, VM
    PHARMACOGENETICS, 2003, 13 (07): : 383 - 388
  • [44] Functional Characterization of Cytochrome P450 2C19 Allelic Variants CYP2C19*23 and CYP2C19*24
    Lau, P. S.
    Leong, K. V. G.
    Ong, C. E.
    Pan, Y.
    PUBLIC HEALTH GENOMICS, 2015, 18 : 25 - 25
  • [45] CYP2C19 gene polymorphism in Ningxia
    Zhen Yang
    Yunqian Xie
    Daya Zhang
    Yan Zou
    Ximei Li
    Runxiang Chen
    Xiaodong Zhang
    Shiju Chen
    Feihu Bai
    Pharmacological Reports, 2023, 75 : 705 - 714
  • [46] CYP2C19 variation and citalopram response
    Mrazek, David A.
    Biernacka, Joanna M.
    O'Kane, Dennis J.
    Black, John L.
    Cunningham, Julie M.
    Drews, Maureen S.
    Snyder, Karen A.
    Stevens, Susanna R.
    Rush, Augustus John
    Weinshilboum, Richard M.
    PHARMACOGENETICS AND GENOMICS, 2011, 21 (01): : 1 - 9
  • [47] CYP2C19 gene polymorphism in Ningxia
    Yang, Zhen
    Xie, Yunqian
    Zhang, Daya
    Zou, Yan
    Li, Ximei
    Chen, Runxiang
    Zhang, Xiaodong
    Chen, Shiju
    Bai, Feihu
    PHARMACOLOGICAL REPORTS, 2023, 75 (03) : 705 - 714
  • [48] CYP2C19 Genotype and Cardiovascular Events
    Siasos, Gerasimos
    Tousoulis, Dimitris
    Stefanadis, Christodoulos
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (14): : 1483 - 1484
  • [49] Clopidogrel, CYP2C19, and a Black Box
    Ford, Neville F.
    Taubert, Dirk
    JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (03): : 241 - 248
  • [50] CYP2C19 genotype: a moving target?
    Zembles, Tracy N.
    Marcuccilli, Charles J.
    Sander, Tara L.
    Simpson, Pippa
    PHARMACOTHERAPY, 2012, 32 (10): : E236 - E236